tv.qiagenbioinformatics.com

Drug Target and Biomarker Investigation using OmicSoft OncoLand

Mon, 25 Aug 2025 10:43:04 GMT

In this 90-minute training, attendees will learn how to use basic expression analysis functionalities in QIAGEN OmicSoft OncoLand. QIAGEN OmicSoft Single Cell Land will also be discussed, focusing on public single-cell data.

Key focus will be on Biomarker discovery with QIAGEN OmicSoft OncoLand leveraging public oncology data from GEO, TCGA and other collections to:

• Discover and validate biomarker expression in diseases, disease subtypes, treatments, cell types, etc.
• Identify a list of biomarkers specifically expressed in disease, treatment group, cell type or other condition of interest
• Overlay expression of a gene on cell clusters of interest from public single-cell data

This training is designed for biologists, bioinformaticians, and data scientists.

Checkpoint inhibitor and immuno-oncology investigation leveraging curated...

Tue, 19 Nov 2024 08:47:30 GMT

While there is great interest in the scientific community to investigate drug targets and biomarkers from public immune-oncology data, such investigation is hindered by the difficulty in finding and combining related datasets to perform large-scale meta-analyses. This webinar will focus on how high-quality curated genomic repositories such as QIAGEN OmicSoft Lands immediately allows in-depth investigations across diverse data sources (GEO, CPTAC, TCGA, GTEx and more) to discover and validate candidate checkpoint inhibitor drug targets and biomarkers.

You will learn how to do the following in the graphical user interface and through APIs:

- Easily identify relevant samples using extensive manually curated clinical metadata

- Visualize and identify checkpoint inhibition biology related drug target and biomarkers expression patterns using expression data (RNA-seq, scRNA-seq, proteomics etc.)

- Reveal how the expression of a group of biomarkers (or genes/proteins of interest) correlates in normal and disease tissue

How to accelerate your clinical reporting workflow for high-throughput...

Sat, 17 Aug 2024 22:22:39 GMT

As the demand for personalized cancer treatment grows, clinical diagnostic labs are facing unprecedented pressure to scale-up, increase test throughput, reduce turnaround times, and deliver comprehensive, oncologist-ready reports that match patients to the most appropriate therapies and clinical trials, in a time-efficient manner.

In this webinar, learn how QIAGEN Clinical Insight (QCI) Interpret for Oncology, the world’s leading variant interpretation and reporting software, can help your lab accelerate your clinical reporting workflow for high-throughput precision oncology NGS testing. The webinar will demonstrate the capabilities and features of QCI Interpret for Oncology through an example workflow for comprehensive genomic profiling. Key highlights include the software’s capability to expedite variant interpretation, dynamically compute pathogenicity and actionability based on the ACMG and AMP/ASCO/CAP guidelines for every variant in over 30,000 cancer types and subtypes with full transparency. Additionally learn how to leverage over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries to build customizable, oncologist-ready reports with up-to-date gene, variant, diagnostic, prognostic and therapeutic information.

Topics covered in this webinar:
- QCI Interpret for Oncology’s new performance and scalability enhancements, including bulk variant assessment, flagging of co-occurring variants, and a somatic reporting policy that allows users to set pathogenicity in a phenotype-agnostic manner.
- Learn how the panel- and sequencer-agnostic software can facilitate true scalability by rendering efficient test and process management capabilities, quick identification and comparison of tests from a patient for follow-up.
- How the software’s underlying knowledge base combines the unmatched accuracy and consistency of QIAGEN’s proprietary expert (MD/PhD) curation with the superior efficiency of machine curation (AI-powered) to identify all the literature, treatments, and clinical trials relevant to a patient’s tumor type with just one-click.

Expert panel: Mitigating variability in somatic variant interpretation

Thu, 06 Jun 2024 19:25:52 GMT

Next-generation sequencing (NGS) oncology panels are becoming integral in hospital and academic settings to guide patient treatment and enrollment in clinical trials. But as NGS is increasingly used in precision oncology and an unprecedented amount of genomic information is uncovered, there is an industry-wide issue of standardization: a high degree of variability in variant interpretation currently exists across laboratories.

Inconsistencies in variant interpretation among laboratories can create confusion for clinicians and their patients, leaving them unable to confidently use genetic information to manage healthcare decisions. In this previously aired live panel discussion, experts in NGS testing and clinical informatics explore the issues surrounding the standardization of variant interpretation and consider how interpretation guidelines and clinical decision support (CDS) software can help to mitigate variability between laboratories.

Topics of discussion include:

Findings of a peer-reviewed study comparing the accuracy and consistency of variant assessments from commercial CDS software to the internal variant interpretation methods of eight laboratories.
Causes of inter-laboratory inconsistency in variant interpretation and how to mitigate variability.
The benefits of having an up-to-date, high-quality knowledge base to produce consistent, evidence-based clinical classifications.

Clinician’s Roundtable: Interpreting genomic test results for precision oncology

Tue, 21 May 2024 15:22:54 GMT

You’re invited to attend the 2024 Clinician’s Roundtable, a virtual event where medical directors and oncologists will discuss how to better interpret genomic test results to tailor treatment strategies for cancer patients. As the role of the Molecular Tumor Board (MTB) becomes increasingly important in the implementation of evidence-based precision cancer medicine programs, molecular pathology labs must overcome challenges in genomic test interpretation to ensure maximum clinical utility of molecular profiling results.

At this event, hear from clinicians at leading universities and organizations as they present real-world case studies of how molecular pathology labs can improve test turnaround, standardize test interpretation, and deliver comprehensive genomic reports with personalized diagnostic, prognostic, and therapeutic information for each patient.

The free-to-attend virtual event will consist of four educational parts:

1. Case Presentations: Clinicians from Dana Farber Cancer Institute and the National Cancer Institute will present cases of how their labs have overcome challenges in genomic test interpretation.

2. Live Q&A Session: Attendees will have the opportunity to ask the clinicians questions about their experiences implementing precision oncology programs at their institutions.

3. Solution Showcase: In a brief presentation, experts from QIAGEN Digital Insights will showcase our leading Sample to Insight solutions for molecular tumor profiling.

4. Future Forecast: The event will conclude with a short presentation about how molecular tumor profiling will change in the next five years and how labs can leverage new technologies to improve patient care.

Using COSMIC to predict, identify, and avoid mutational consequences of...

Mon, 11 Mar 2024 13:14:49 GMT

Whether your lab is researching and developing targeted cancer therapies or you are analyzing and interpreting diagnostic tests at the point-of-care, a critical part of your workflow is understanding the structural and functional impact of cancer-related mutations.

The Catalogue Of Somatic Mutations In Cancer (COSMIC) is an expert-curated database encompassing a wide variety of somatic mutation mechanisms causing human cancer. Containing more than 24 million somatic variants with detailed information on mutation distribution, effects, and signatures, COSMIC helps users better predict the cancer-driving effects of mutations and identify available drugs that target specific variants. COSMIC continues to expand its utility with continuous updates to its Mutational Signatures, the Cancer Mutation Census, and Mutation Actionability in Precision Oncology products.

To illustrate key applications of these features, this webinar focuses on how COSMIC can be used to avoid mutational consequences in cancer drug development and to profile the mutational signatures of cancer therapies in clinical samples.

Through these clinical and discovery use cases, attendees will learn:

· How to evaluate genomic loci using the comprehensive coding and non-coding variant annotations within COSMIC

· How to integrate these variants with curated findings and summaries of mutational impact and clinical actionability

· How mutational signatures could be useful for clinical diagnosis and drug development applications now and in the future

How clinical labs can confidently assess cancer-associated variants with...

Thu, 07 Dec 2023 14:18:44 GMT

Across various stages of the clinical oncology workflow, from panel design to genomic testing and molecular tumor boards, the identification and validation of actionable genomic alterations is critical. The advent of next-generation sequencing (NGS) has led to an exponential increase in the number of variants detected in tumor testing, posing a challenge for clinical cancer genetics professionals seeking to confidently discern clinically relevant mutations that can guide patient care decisions.

Join Dr. Umadevi Thirumurthi, Associate Director of Global Product Management for Oncology at QIAGEN Digital Insights as she discusses how the Human Somatic Mutation Database (HSMD), an expert-curated somatic variant database, can enhance your clinical NGS workflow.

How to scale-up comprehensive genomic profiling and deliver confident variant...

Fri, 10 Nov 2023 13:58:00 GMT

As gene panels increase in size, comprehensive genomic profiling and variant interpretation becomes more complex and time-consuming, which places tremendous burden on labs needing to scale and grow case volume. QIAGEN Clinical Insight (QCI) Interpret for Oncology is a clinical decision support platform powered by augmented molecular intelligence that enables rapid, evidence-powered comprehensive genomic profiling at scale. QCI Interpret for Oncology is supported by the world’s most comprehensive, manually curated knowledge base and dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines with transparency. Users also get access to over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries and can build customizable, oncologist-ready reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapeutic information and clinical trial recommendations. With its latest release, QCI Interpret for Oncology adds several new capabilities that further enhances the platform’s scalability and flexibility, and enables users to significantly reduce variant research and review time.

In this webinar, attendees will learn how QCI Interpret for Oncology enables you to:

Navigate from VCF to final report with speed, precision, and confidence;
Easily issue report addendums without the need for re-running a VCF;
Streamline structural variant filtering based on user set thresholds and hence reduce the time and effort needed to eliminate noise and identify truly relevant variants for reporting;
Utilize built-in AI capabilities to identify all the literature, case reports, drug therapies, and clinical studies relevant to a patient’s tumor type with just one-click.

Circulating Tumor Cell Detection and Analysis to Support Malignancy...

Wed, 25 Oct 2023 14:11:11 GMT

Circulating tumor cells (CTCs) are cells that leave the primary tumor and are intravasated into the blood circulation system. A subset of those make it to other organs and are responsible for metastasis. iCellate’s CellMate platform is a CTC-based liquid biopsy for cancer cell enrichment, detection, and biomarker analysis via a simple blood draw.

In this seminar, you’ll learn:

From Helena Silva Cascales, senior scientist at iCellate Medical AB, how the isolation of whole-tumor cells provides a more comprehensive biomarker analysis, including genomic sequencing and multiplexed protein expression analysis.
From Kashyap Dave, principal scientist at iCellate Medical AB, how DNA from single CTCs can be amplified, sequenced, and analyzed to support malignancy designation and tissue of origin identification using classification analyses under development within Qiagen CLC Genomics Workbench.

Real-World Applications of Clinical Metagenomic Sequencing in Cancer and...

Wed, 25 Oct 2023 13:25:00 GMT

Clinical metagenomic next-generation sequencing (mNGS), the comprehensive analysis of microbial and host DNA and RNA in samples from patients, is rapidly moving from research to clinical laboratories. This emerging approach is changing the diagnosis and treatment of diseases, with applications in a range of areas, including oncology, human host gene expression (transcriptomics), and antimicrobial infections and resistance.

In this webinar, Elif Dagdan, the director of the Center for Medical Genetics at Augusta Hospital Bochum in Bochum, Germany, will discuss real-world applications of using clinical mNGS to improve diagnostics of cancer and infectious diseases. The talk will also feature challenges and opportunities of using mNGS in disease diagnostics and how Dagdan’s lab uses clinical variant interpretation and reporting software from Qiagen to detect and characterize pathogenic somatic variants.

Dagdan will discuss:

How mNGS can be used to assess homologous recombination deficiency (HRD) status in patients with ovarian cancer.
How mNGS can be used to assess cell-free microbial DNA via liquid biopsy to aid in early-stage lung cancer diagnosis.
How mNGS can improve the accuracy and speed of infectious disease diagnostics, with a use-case on cardiovascular infections in intensive care units.

Indication Expansion and Repurposing of PIK3CA Kinase Inhibitors: Systems...

Wed, 20 Sep 2023 07:38:56 GMT

Here we demo tools to rapidly guide drug repurposing and indication expansion, using alpelisib—a PI3Kα inhibitor approved for metastatic breast cancer—as a case study. The speaker shows how activating mutations in the PIK3CA gene, a key oncogene, not only prevalent in breast cancer but also significantly present in oral cancers, an area with few active clinical trials and limited therapeutic development. By merging real-world mutation data, clinical outcomes, and pathway-based network modeling, the analysis shows that PIK3CA mutations in oral cancer correlate with poorer survival, and that inhibiting PIK3CA activity could reduce disease progression. Further, the session used public dataset comparisons to identify non-oncologic diseases (e.g., lupus, heart disease) that share similar biology, suggesting future repurposing potential. It concluded by identifying possible combination therapy partners through anti-matching expression patterns, showcasing a full workflow from hypothesis generation to target validation in under an hour.

Scale your comprehensive genomic profiling workflow with superior automated...

Wed, 28 Jun 2023 16:02:07 GMT

Automating and scaling a comprehensive genomic profiling workflow can be a tedious and challenging process that requires lots of time and resources. However, an intelligent clinical decision support platform and on-demand expert support services can make all the difference.

In this webinar, learn about QIAGEN Clinical Insight (QCI) Interpret for Oncology, a clinical decision support platform that has been trusted to analyze and interpret more than 3 million patient molecular profiles worldwide. Unlike other commercial solutions, QCI Interpret for Oncology is powered by augmented molecular intelligence and offers in-software access to a team of variant scientists to assist you with rare or novel variant research, curation, and interpretation. The platform connects to the QIAGEN Knowledge Base—the highest quality genomic knowledge base in the industry—and dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines. To help you further scale and reduce hands-on time, QCI Interpret for Oncology provides over 410,000 variant interpretation summaries that have all been reviewed by oncologists. This enables you to quickly build custom reports for your oncologists and their patients with the latest diagnostic and prognostic information, as well as biomarker-directed therapy and clinical trial recommendations.

By attending viewing this webinar, you will:

Receive a step-by-step guide of how to go from VCF to final report using QCI Interpret for Oncology
Learn about the platform’s automated variant classification process
Learn how QIAGEN uses augmented molecular intelligence to enhance our expert curation process
See first-hand how to build a custom report with an opportunity to submit your own VCF file for a sample report

2023 Clinical Oncology Summit: Part 2 - NA

Fri, 26 May 2023 14:12:24 GMT

How to improve your existing pipeline for somatic mutation analysis, interpretation and reporting

We are excited to bring thought leaders, NGS experts, lab directors, variant scientists, clinicians, and oncologists under one virtual roof at our second annual Clinical Oncology Summit hosted on April 27 and May 18, 2023.

The two-part, content-rich event will feature invited lectures from lab directors and clinical geneticists, thought-provoking discussions on the future of comprehensive genomic profiling, and educational presentations on the latest databases, software, and services for somatic secondary and tertiary analysis. Designed to help clinical diagnostic labs understand how they can optimize their current pipelines for somatic NGS analysis, interpretation and reporting, the Clinical Oncology Summit is a must-attend event for labs who need to reduce turnaround time, improve operational costs, and scale for higher throughput.

2023 Clinical Oncology Summit: Part 2 - EMEA

Fri, 26 May 2023 14:11:25 GMT

How to improve your existing pipeline for somatic mutation analysis, interpretation and reporting

2023 Clinical Oncology Summit: Part 1 - Americas

Mon, 01 May 2023 19:30:14 GMT

How to improve your existing pipeline for somatic mutation analysis, interpretation and reporting
We are excited to bring thought leaders, NGS experts, lab directors, variant scientists, clinicians, and oncologists under one virtual roof at our second annual Clinical Oncology Summit.

2023 Clinical Oncology Summit: Part 1 - EMEA

Thu, 27 Apr 2023 19:31:29 GMT

How to improve your existing pipeline for somatic mutation analysis, interpretation and reporting

We are excited to bring thought leaders, NGS experts, lab directors, variant scientists, clinicians, and oncologists under one virtual roof at our second annual Clinical Oncology Summit.

Meet the speakers and view the full agenda here.

Comprehensive Molecular Tumor Analysis with Alacris Theranostics

Thu, 09 Mar 2023 16:16:33 GMT

Precision oncology approaches have made great strides harnessing individual tumor mutation profiles to guide targeted therapy choices. However, deeper molecular insights are needed to improve personalized treatment decisions. Integrating gene expression analysis in personalized oncology provides an additional level of insight. These analyses include evaluating expressed mutations and drug targets, novel gene fusions, clinically relevant signatures, and the tumor immune microenvironment (TME).

Alacris Theranostics developed the Comprehensive Molecular Tumor Analysis (CMTA), a NGS-based tumor diagnostic test. The test integrates whole exome and transcriptomic sequencing (WES and RNAseq). The test deploys as an end-to-end accredited diagnostic platform from tumor sample uptake (FFPE or frozen) to personalized clinical interpretation reports. CMTA is a tumor-agnostic test that displays a unique molecular view of each sample. CMTA is a useful approach for refractory cancers with complex patterns or tumors of unknown origin.

In this webinar, viewers will:

Learn about the strategy implemented in Alacris’ bioinformatics pipeline to identify cancer-relevant somatic events
Learn how Alacris uses QCI Interpret for Oncology to annotate variants and identify potential therapies
Be eligible for a complimentary QCI Interpret demo and sample report

Discoveries from public immuno-oncology studies using Omicsoft and Ingenuity...

Thu, 12 Jan 2023 17:24:47 GMT

This training will focus on how QIAGEN Omicsoft Studio and Ingenuity Pathway Analysis (IPA) can be used to discover new biomarkers, validate (or study) drug targets and identify novel mechanism of action with user and/or public Immuno-Oncology studies from resources like GEO, SRA, TCGA and more.
Attendees will learn how to
• Investigate expression of a gene/biomarker/drug target across different treatments and diseases
• Derive a biomarker/gene signature from specific condition (example non-responders of a drug, a specific disease/disease subtype and more)
• Correlate expression of multiple genes and biomarkers
• Compare different experimental groups (user and/or public data) at both gene expression and pathways/regulatory networks activity levels

Somatic variants investigation in critical regulatory pathways

Thu, 25 Aug 2022 15:10:11 GMT

This training will focus on using QIAGEN Ingenuity Pathway analysis (IPA) and Human Somatic Mutation Database (HSMD) to identify key somatic variants associated with regulatory genes in ‘omic data and study the genomic characteristics of both target and disease to better understand the clinical relevance. Identifying and studying the genomic characteristics of drug targets and important genes are of great interest to many researchers as it can offer new insights into improving drug discovery and precision medicine. In this 90-minute training, the Human Somatic Mutation Database (HSMD) will be introduced for genomic investigation. HSMD is a web-based database containing data for hundreds of thousands of variants within the context of solid tumors and hematological malignancies. Specifically, HSMD provides gene-level, alteration-level, and disease-level information including clinically observed gene and variant frequencies across cancer types.

Attendees will learn how to:

· Use IPA to identify key regulators within a dataset of interest

· Use HSMD to investigate variants for target genes and cancer type of interest

· Synthesize key findings from drug labels, clinical trials, and PubMed articles for specific alterations and cancer types

Click here to learn more about HSMD and IPA.

50 to 500 genes: Scale-up to comprehensive genomic profiling

Wed, 13 Jul 2022 08:28:03 GMT

In this webinar, we present a workflow-agnostic, informatics software solution that enables clinical diagnostic labs to scale to CGP while reducing cost, time, and labor. Already used and trusted to interpret over 3 million patient cases worldwide, this software solution leverages the world’s largest and fastest-growing knowledge base to simplify and accelerate variant interpretation and build custom, patient-specific reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapies and clinical trials.

In this webinar, you will:

Learn how to overcome unique challenges of CGP, including identifying incidental germline findings and interpreting co-occurring variants.
See why 90,000 users trust QIAGEN Digital Insights for knowledge curation—how we have built the most trusted, fastest growing knowledge base and why our curation process is unrivalled in the industry.
Receive step-by-step guide of how to perform CGP and go from VCF to final report with greater speed, precision, and confidence (all registrants can receive custom report if VCF files are provided).
Qualify for a complimentary demonstration and trial of this industry-leading software to see how your lab can scale to CGP while reducing costs, time, and labor.

Lower the barrier to adopt larger CGP in Dx labs: QIAGEN Expert Talks in US

Fri, 27 May 2022 17:55:59 GMT

A two-part event, the Break the Data Bottleneck Summit will explore how small to mid-sized clinical diagnostic labs can compete to offer comprehensive genomic profiling services for precision oncology with the same speed and confidence of large hospital networks and university centers.

Featured topics at the event include:

Expert tips to improve the accuracy and efficiency of your molecular tumor boards
How to accelerate your bioinformatics pipeline from FASTQ to report
How your lab can stay up-to-date on guidelines, therapies, and clinical trials

Part 1: May 19, 2022 (Americas and Europe)

QIAGEN Expert Talks

Part 2: June 16, 2022 (Americas) and June 21, 2022 (Europe)

Customer Insights

Lower the barrier to adopt larger CGP in Dx labs: QIAGEN Expert Talks in Europe

Fri, 27 May 2022 17:55:04 GMT

Expert tips to improve the accuracy and efficiency of your molecular tumor boards
How to accelerate your bioinformatics pipeline from FASTQ to report
How your lab can stay up-to-date on guidelines, therapies, and clinical trials

Part 1: May 19, 2022 (Americas and Europe)

QIAGEN Expert Talks

Access to real-world data and 2 decades of expert curation

Wed, 20 Apr 2022 07:43:42 GMT

Across oncology applications, from research to molecular testing and pharmaceutical development, the ability to identify potentially actionable genetic alterations and exploit the molecular vulnerabilities of cancer is becoming increasingly difficult. Due to the sporadic nature of somatic cancers, the number of detected variants is exponentially growing, challenging scientists to confidently identify meaningful mutations that could influence or improve decisions in experimental design, at point-of-care, or in drug development.

In this webinar, we will introduce you to the Human Somatic Mutation Database (HSMD)—a new somatic database developed by QIAGEN that contains extensive genomic content relevant to solid tumors and hematological malignancies. Available as a web-based application, this expert-curated resource contains content from over 300,000 real-world clinical oncology cases combined with content from the QIAGEN Knowledge Base, providing gene-level, alteration-level, and disease-level information including clinically observed gene and variant frequencies across diseases. Users can easily search and explore mutational characteristics across genes, synthesize key findings from drug labels, clinical trials, and professional guidelines, and receive detailed annotations for each observed variant. In addition, users can interrogate a bibliography of over 150,000 variant specific PubMed articles and access individual summaries alteration-type specific information written by PhD scientists.

In this webinar, you will learn:

What content sources power HSMD
How to use and apply HSMD for multiple applications, including research, molecular testing, and pharmaceutical development
When and where you can access HSMD

Identify meaningful mutations in somatic tumor testing

Mon, 14 Feb 2022 14:54:55 GMT

From Information Overload to Actionable Insights

Precision medicine is transforming cancer care, with next-generation sequencing (NGS) enabling the simultaneous analysis of multiple genomic alterations with therapeutic implications. However, due to the sporadic nature of somatic cancers and the increasing uptake of NGS testing, the number of detected variants is exponentially growing, challenging labs to confidently identify meaningful mutations that could influence or improve decisions at the point of care. Approximately 50 percent of the oncologists in the United States find NGS results sometimes or often difficult to interpret, while 31 percent of small to medium-sized labs in Europe view a lack of knowledge and exposure to routine analyses and interpretation as the most critical bottleneck in NGS testing [1-2].

In this webinar, Ana Krivokuca will present a real-world use case of how the Institute for Oncology and Radiology of Serbia (IORS), a national cancer research center that provides routine NGS testing for cancer patients, uses the Human Somatic Mutation Database (HSMD) in their NGS testing pipeline to validate, assess, and better understand the clinical significance of detected variants.

A new somatic database from QIAGEN, HSMD combines two decades of expert-curated content with data from over 300,000 real-world clinical oncology cases to provide deep genomic insight into the molecular characterizations of a patient’s tumor. Easy to search with new content added weekly, HSMD enables users to explore key genes or mutations with driving properties or clinical relevance, search for associated treatment options, evaluate secondary findings, and develop customized gene panels.

Attendees will:

Learn how IORS uses HSMD to identify actionable variants, analyze complex reports, evaluate secondary findings, and design custom gene panels.
Explore HSMD content and features through a virtual demonstration.
Receive a complimentary, five-day trial of HSMD.

Speaker:
Ana Krivokuca, PhD
Head of Department for Genetic Counseling
Institute for Oncology and Radiology of Serbia